Compassionate Use of Evinacumab

NCT ID: NCT06500598

Last Updated: 2025-10-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

APPROVED_FOR_MARKETING

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Provide compassionate use of evinacumab

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Homozygous Familial Hypercholesterolemia (HoFH) Severe Hypertriglyceridemia (HTG) Dysbetalipoproteinemia (DBL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Evinacumab

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

REGN1500 EVKEEZA®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Eligible Sex

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Regeneron Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R1500-Evinacumab

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of BHV-1400 in IgA Nephropathy
NCT07054684 RECRUITING PHASE1
Itacitinib for Low Risk GVHD
NCT03846479 COMPLETED PHASE2
Ibrutinib and Rituxan for Chronic GVHD
NCT04235036 TERMINATED PHASE2